Home
Product
Antibody
Biosimilar Antibodies
TPBG (PF-06263507 Biosimilar) Recombinant Monoclonal Antibody

TPBG (PF-06263507 Biosimilar) Recombinant Monoclonal Antibody

Code: CSB-RA024093MB2HU

Rate （N/A）
Review （0）

Size:

100ug

100ug500ug1mg5mg10mg50mg100mg200mg

US$199

Quantity:

Species Reactivity: Human

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot NO.

Q13641

Alternative Names

Trophoblast glycoprotein antibody; 5T4 oncofetal antigen antibody; 5T4 oncofetal trophoblast glycoprotein；5T4 oncotrophoblast glycoprotein antibody; M6P1 antibody; Wnt-activated inhibitory factor 1；WAIF1 antibody; TPBG antibody; 5T4

Species Reactivity

Human

Immunogen

Recombinant Human TPBG protein

Conjugate

Non-conjugated

Clonality

Monoclonal

Buffer

0.01M PBS，pH7.4

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Notes

Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity > 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.

Lead Time

In stock
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Concentration

It differs from different batches. Please contact us to confirm it.

Usage

It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

Datasheet & COA

Antibody FAQs

Description

This recombinant monoclonal antibody is developed as a research-grade biosimilar to PF-06263507, targeting trophoblast glycoprotein (TPBG), also known as 5T4 or Wnt-activated inhibitory factor 1 (WAIF1). TPBG is a leucine-rich repeat glycoprotein that functions as a Wnt signaling modulator and is highly expressed during embryonic development and trophoblast differentiation. This antigen exhibits restricted expression in normal adult tissues but becomes aberrantly overexpressed in numerous malignancies, including colorectal, ovarian, gastric, and non-small cell lung cancers, where it correlates with poor prognosis, enhanced metastatic potential, and cancer stem cell properties.

PF-06263507 represents a TPBG-targeting antibody-drug conjugate (ADC) that exhibited anti-tumor potential in preclinical studies. This biosimilar antibody serves as a valuable research tool for investigating TPBG biology, tumor microenvironment interactions, and cancer stem cell mechanisms. It enables researchers to explore TPBG as a therapeutic target and biomarker in oncology research, facilitating studies in tumor immunology, metastasis, and targeted therapy development.

Customer Reviews and Q&A

■ Customer Reviews

Submit a Review here

Target Background

Function(From Uniprot)

May function as an inhibitor of Wnt/beta-catenin signaling by indirectly interacting with LRP6 and blocking Wnt3a-dependent LRP6 internalization.

Gene References into Functions

In extravillous trophoblasts, 5T4 may function in epithelial-to-mesenchymal transition during placentation. The role of syncytiotrophoblast 5T4 is unknown, but its abundance in shed syncytial vesicles may signify route of sensitization of the maternal immune system. PMID:28481180
Collectively, these findings demonstrate that an anti-5T4 antibody-drug conjugate reduces the fraction of cancer stem cells (CSC), and prevents local recurrence and suggest a novel therapeutic approach for patients with head and neck squamous cell carcinoma. PMID:27780858
We obtained GWS evidence (P < 2.7 x 10(-6)) for gene-based association in the total sample with a novel locus, TPBG (P = 1.8 x 10(-6)). PMID:28183528
In conclusion, the present study provided evidence that TPBG is involved in PDAC metastasis, and that TPBG and its associated signaling pathways may be a suitable target for pancreatic ductal adenocarcinoma therapy. PMID:25738465
5T4 expression is mechanistically associated with the directional movement of cells through epithelial mesenchymal transition, facilitation of CXCL12/CXCR4 chemotaxis, blocking of canonical Wnt/beta-catenin while favouring non-canonical pathway signalling PMID:25066861
Tyrosine 325 plus the leucine-rich repeat 1 surface centered on a second exposed aromatic residue, phenylalanine 97, are essential for inhibition of Wnt/beta-catenin signaling. PMID:24582434
The surface expression of 5T4 marks the use of the CXCR4 rather than the CXCR7 receptor, with distinct consequences for CXCL12 exposure. PMID:22956548
5T4 is a potential new antigen for targeted therapies such as immunotherapy in MPM, as it is overexpressed on mesothelioma cells and recognised by 5T4-specific cytotoxic T-cells. PMID:22498111
Glycosylation and epitope mapping of the 5T4 glycoprotein oncofoetal antigen PMID:11903056
Results sugest that 5T4 is a transient marker of human embryonic stem cell differentiation & that 5T4 phenotype, colony seeding density and culture conditions influence the maintenance of pluripotent hES cells and their differentiation to neural lineages. PMID:16616918
there is a repertoire of CD8 T cell recognition of 5T4 in normal human donors and some candidate HLA-A*0201 epitopes have been identified PMID:16646078
the mRNA expression of trophoblast glycoprotein is up-regulated in cells circulating within blood from women with preeclampsia. PMID:17978129
5T4-based cancer vaccine: cytotoxic T lymphocyte epitopes identified in Trovax-vaccinated colorectal cancer patients PMID:18567615
colorectal cancer patients who had preexisting cell proliferative responses to 5T4 were longer-term survivors PMID:18833005

Hide All

Subcellular Location

Cell membrane; Single-pass type I membrane protein.

Tissue Specificity

Expressed by all types of trophoblasts as early as 9 weeks of development. Specific for trophoblastic cells except for amniotic epithelium. In adult tissues, the expression is limited to a few epithelial cell types but is found on a variety of carcinoma.

Database Links

HGNC: 12004

UNIGENE: Hs.71947

KEGG: hsa:7162

STRING: 9606.ENSP00000358765

OMIM: 190920

Promotions